Arcoxia
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
In addition to adequate surgical fixation and an aggressive rehabilitation program, pain relief is one of the most critical…
Summary Dysmenorrhoea is painful menstruation that occurs in 45–72% of all women. This was a prospective randomised study of the…
GAITHERSBURG, Md. -- By a vote 20 to one, FDA advisers recommended today against approval of Merck's Cox-2 inhibitor etoricoxib…
Nonsteroidal antiinflammatory drugs (NSAIDs) are modestly effective at best for relieving pain in patients with arthritis, said…
At the end of September 2004, Merck & Co announced the voluntary withdrawal of rofecoxib (Vioxx) worldwide because of an…
L'etoricoxib (Arcoxia®) est un nouvel anti-inflammatoire non steroidien (AINS) inhibant selectivement la forme inductible de la…
Cyclooxygenase-2 selective inhibitors (COXIB or CSI) have been released with a fanfare as efficacious and safer alternatives to…